The US Food and Drug Administration (FDA) has granted Fast Track designation for Anthos Therapeutics’ fully human monoclonal antibody abelacimab to investigate it for preventing stroke and systemic embolism in atrial fibrillation (AF) patients.

The new dual-acting, once-monthly antibody abelacimab has been designed for inducing hemostasis-sparing anticoagulation through inhibition of Factor XI.

Related Company Profiles

View all

Targeting Factor XI’s active domain, the antibody shows dual inhibitory activity against Factor XI as well as its activated form, Factor XIa, with high selectivity and affinity.

The latest move marks the second Fast Track designation granted by FDA to abelacimab.

In July, the antibody received the Fast Track designation to treat cancer-associated thrombosis (CAT).

See Also:

It has also become the first Factor XI inhibitor to commence subject enrolment in Phase III trials earlier this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Anthos Therapeutics chief medical officer Dan Bloomfield said: “Real-world evidence has shown that adherence to current therapies is less than ideal for many patients, including those with atrial fibrillation and cancer-associated thrombosisi. This non-adherence may be associated with an increased risk of stroke.

“With one in four people dying from thromboembolic events globally, the need to do better is urgent.

“As a company, we remain highly committed to working closely with the FDA to bring once monthly abelacimab to patients in need.”

The company stated that abelacimab gave intravenously (IV) suppressed Factor XI within one hour of the treatment and maintained near maximal inhibition for up to 30 days in a PK/PD study.

Additionally, a single IV abelacimab dose following a knee surgery showed an 80% reduction in venous thromboembolism rate compared to enoxaparin in a Phase II study.